171 related articles for article (PubMed ID: 21470582)
1. [Nasal septum perforation and bevacizumab].
Bengrine-Lefevre L; Afchain P; Chibaudel B; Gervais H; Tournigand C; De Gramont A; Louvet C
Rev Med Interne; 2011 Apr; 32(4):e43-5. PubMed ID: 21470582
[TBL] [Abstract][Full Text] [Related]
2. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.
Traina TA; Norton L; Drucker K; Singh B
Oncologist; 2006; 11(10):1070-1. PubMed ID: 17110625
[No Abstract] [Full Text] [Related]
3. Nasal septum perforation in a breast cancer patient treated with bevacizumab.
Marín AP; Sánchez AR; Arranz EE
Ann Oncol; 2009 Nov; 20(11):1901-2. PubMed ID: 19752003
[No Abstract] [Full Text] [Related]
4. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.
Burkart CM; Grisel JJ; Hom DB
Laryngoscope; 2008 Sep; 118(9):1539-41. PubMed ID: 18622319
[TBL] [Abstract][Full Text] [Related]
5. A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer.
Petrelli F; Cabiddu M; Barbara C; Barni S
Breast Cancer; 2011 Jul; 18(3):226-30. PubMed ID: 21312011
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.
Rodriguez CA; Martin T; Lozano R; Gomez A; Cruz JJ
Breast J; 2017 Nov; 23(6):745-746. PubMed ID: 28845572
[TBL] [Abstract][Full Text] [Related]
7. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients.
Mailliez A; Baldini C; Van JT; Servent V; Mallet Y; Bonneterre J
Br J Cancer; 2010 Sep; 103(6):772-5. PubMed ID: 20736943
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-induced nasal septum perforation.
Fakih MG; Lombardo JC
Oncologist; 2006 Jan; 11(1):85-6. PubMed ID: 16401718
[No Abstract] [Full Text] [Related]
9. Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.
Ramiscal JA; Jatoi A
Acta Oncol; 2011 May; 50(4):578-81. PubMed ID: 21108568
[TBL] [Abstract][Full Text] [Related]
10. Nasal septum perforation and bevacizumab.
Power DG; Kemeny NE
Med Oncol; 2011 Mar; 28(1):89-93. PubMed ID: 20213219
[TBL] [Abstract][Full Text] [Related]
11. [Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].
Mychaluk J; Piprot C; Sevestre H; Merviel P; Gondry J; Fauvet R
Presse Med; 2009 Sep; 38(9):1370-4. PubMed ID: 19349140
[No Abstract] [Full Text] [Related]
12. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A
Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040
[TBL] [Abstract][Full Text] [Related]
13. Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab.
Lazzati V; Zygoń J; Lohsiriwat V; Veronesi P; Petit JY
Aesthetic Plast Surg; 2010 Dec; 34(6):796-7. PubMed ID: 20567970
[No Abstract] [Full Text] [Related]
14. Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel.
Philippin-Lauridant G; Thureau S; Ouvrier MJ; Blot E
Ann Oncol; 2008 Nov; 19(11):1977-8. PubMed ID: 18801882
[No Abstract] [Full Text] [Related]
15. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer.
Ruiz N; Fernandez-Martos C; Romero I; Pla A; Maiquez J; Calatrava A; Guillem V
J Clin Oncol; 2007 Aug; 25(22):3376-7. PubMed ID: 17664487
[No Abstract] [Full Text] [Related]
16. Bevacizumab: new indication. Metastatic breast cancer: many adverse effects.
Prescrire Int; 2008 Dec; 17(98):236. PubMed ID: 19422148
[No Abstract] [Full Text] [Related]
17. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
18. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Chen S; Karnezis T; Davidson TM
Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
[TBL] [Abstract][Full Text] [Related]
19. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
20. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
